Cell cycle-related kinase is a direct androgen receptor-regulated gene that drives β-catenin/T cell factor-dependent hepatocarcinogenesis

Journal of Clinical Investigation

Volumn 121, Issue 8, 2011, Pages 3159-3175

  Feng, Hai ^a   Cheng, Alfred S L ^a   Tsang, Daisy P ^a   Li, May S ^a   Go, Minnie Y ^a   Cheung, Yue S ^a   Zhao, Gui Jun ^b   Ng, Samuel S ^c   Lin, Marie C ^a   Yu, Jun ^a   Lai, Paul B ^a   To, Ka F ^a   Sung, Joseph J Y ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b INNER MONGOLIA UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BANP PROTEIN; BETA CATENIN; CELL CYCLE RELATED KINASE; CELL NUCLEUS ANTIGEN; CYCLIN D1; CYCLIN DEPENDENT KINASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; HPGD PROTEIN; MAPRE2 PROTEIN; MEN1 PROTEIN; PRC1 PROTEIN; PROTEIN KINASE; T CELL FACTOR PROTEIN; TACC3 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENETIC REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; MALE; MALIGNANT TRANSFORMATION; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; UPREGULATION;

AGED; ANIMALS; BETA CATENIN; BINDING SITES; CELL CYCLE; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM TRANSPLANTATION; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TCF TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 79961013561     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI45967     Document Type: Article

References (67)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-543. (Pubitemid 33586866)
2. Yu MW, Chen CJ. Elevated serum testosterone levels and risk of hepatocellular carcinoma. Cancer Res. 1993;53(4):790-794.
3. Shiratori Y, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B-and C- viral infection in Japan. Hepatology. 1995; 22(4 pt 1):1027-1033.
4. Lee CM, et al. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer. 1999;86(7):1143-1150.
5. Yu MW, et al. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst. 2001;93(21):1644-1651.
6. De Maria N, Manno M, Villa E. Sex hormones and liver cancer. Mol Cell Endocrinol. 2002;193(1-2):59-63. (Pubitemid 34823607)
7. Yeh SH, Chen PJ. Gender disparity of hepatocellular carcinoma: the roles of sex hormones. Oncology. 2010;78 suppl 1:172-179.
8. Naugler WE, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121-124. (Pubitemid 47056470)
9. Toh YC. Effect of neonatal castration on liver tumor induction by N-2-fluorenylacetamide in suckling BALB/c mice. Carcinogenesis. 1981;2(11):1219-1221. (Pubitemid 12171137)
10. Kemp CJ, Leary CN, Drinkwater NR. Promotion of murine hepatocarcinogenesis by testosterone is androgen receptor-dependent but not cell autonomous. Proc Natl Acad Sci U S A. 1989;86(19):7505-7509. (Pubitemid 19254484)
11. Zender L, Kubicka S. Androgen receptor and hepatocarcinogenesis: what do we learn from HCC mouse models? Gastroenterology. 2008;135(3):738-740.
12. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20(13):3001-3015. (Pubitemid 34728896)
13. Chiu CM, et al. Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level. Proc Natl Acad Sci U S A. 2007;104(8):2571-2578.
14. Kanda T, Steele R, Ray R, Ray RB. Hepatitis C virus core protein augments androgen receptor-mediated signaling. J Virol. 2008;82(22):11066-11072.
15. Yang WJ, et al. Hepatitis B virus X protein enhances the transcriptional activity of the androgen receptor through c-Src and glycogen synthase kinase-3beta kinase pathways. Hepatology. 2009;49(5):1515-1524.
16. Nagasue N, Ito A, Yukaya H, Ogawa Y. Androgen receptors in hepatocellular carcinoma and surrounding parenchyma. Gastroenterology. 1985;89(3):643-647. (Pubitemid 15239171)
17. Nagasue N, et al. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resection. Ann Surg. 1989;209(4):424-427. (Pubitemid 19106272)
18. Ma WL, et al. Androgen receptor is a new potential therapeutic target for the treatment of hepatocellular carcinoma. Gastroenterology. 2008;135(3):947-955.
19. Wu MH, et al. Androgen receptor promotes hepatitis B virus-induced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci Transl Med. 2010;2(32):32ra35.
20. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557-2576. (Pubitemid 46890874)
21. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45(5):1298-1305. (Pubitemid 46775794)
22. Chiba T, et al. Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer initiation. Gastroenterology. 2007;133(3):937-950. (Pubitemid 47374130)
23. Zeng G, Apte U, Cieply B, Singh S, Monga SP. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 2007;9(11):951-959. (Pubitemid 350086440)
24. Barker N, Clevers H. Mining the Wnt pathway for cancer therapeutics. Nat Rev Drug Discov. 2006;5(12):997-1014. (Pubitemid 44835127)
25. Wang SH, Yeh SH, Lin WH, Wang HY, Chen DS, Chen PJ. Identification of androgen response elements in the enhancer I of hepatitis B virus: a mechanism for sex disparity in chronic hepatitis B. Hepatology. 2009;50(5):1392-1402.
26. Cheng AS, et al. Combinatorial analysis of transcription factor partners reveals recruitment of c-MYC to estrogen receptor-alpha responsive promoters. Mol Cell. 2006;21(3):393-404. (Pubitemid 43163534)
27. Kondo Y, et al. Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet. 2008;40(6):741-750. (Pubitemid 351748874)
28. Qin H, et al. An integrative ChIP-chip and gene expression profiling to model SMAD regulatory modules. BMC Syst Biol. 2009;3:73.
29. Boonyaratanakornkit V, Edwards DP. Receptor mechanisms mediating non-genomic actions of sex steroids. Semin Reprod Med. 2007;25(3):139-153. (Pubitemid 46676901)
30. Balk SP, Knudsen KE. AR, the cell cycle, and prostate cancer. Nucl Recept Signal. 2008;6:e001.
31. Jie X, et al. Androgen activates PEG10 to promote carcinogenesis in hepatic cancer cells. Oncogene. 2007;26(39):5741-5751. (Pubitemid 47312814)
32. Mukherji M, et al. Genome-wide functional analysis of human cell-cycle regulators. Proc Natl Acad Sci U S A. 2006;103(40):14819-14824. (Pubitemid 44527812)
33. Massie CE, et al. New androgen receptor genomic targets show an interaction with the ETS1 transcription factor. EMBO Rep. 2007;8(9):871-878. (Pubitemid 350001432)
34. Firestein R, et al. CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature. 2008;455(7212):547-551.
35. Staal FJ, Noort Mv M, Strous GJ, Clevers HC. Wnt signals are transmitted through N-terminally dephosphorylated beta-catenin. EMBO Rep. 2002;3(1):63-68. (Pubitemid 34144817)
36. Thornton TM, et al. Phosphorylation by p38 MAPK as an alternative pathway for GSK3beta inactivation. Science. 2008;320(5876):667-670. (Pubitemid 351928349)
37. Tan X, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology. 2005;129(1):285-302. (Pubitemid 41002061)
38. Patil MA, et al. Role of cyclin D1 as a mediator of c-Met- and beta-catenin-induced hepatocarcinogenesis. Cancer Res. 2009;69(1):253-261.
39. Liu S, et al. Inappropriate activation of androgen receptor by relaxin via beta-catenin pathway. Oncogene. 2008;27(4):499-505.
40. Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate- resistant prostate cancer. Cancer Res. 2008;68(23):9918-9927.
41. Gordon V, et al. CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol. 2010;24(12):2267-2280.
42. Graham TA, Weaver C, Mao F, Kimelman D, Xu W. Crystal structure of a beta-catenin/Tcf complex. Cell. 2000;103(6):885-896.
43. Gottardi CJ, Wong E, Gumbiner BM. E-cadherin suppresses cellular transformation by inhibiting beta-catenin signaling in an adhesion-independent manner. J Cell Biol. 2001;153(5):1049-1060.
44. Ng SS, et al. Cell cycle-related kinase: a novel candidate oncogene in human glioblastoma. J Natl Cancer Inst. 2007;99(12):936-948. (Pubitemid 47073500)
45. Yu MW, et al. Androgen-receptor gene CAG repeats, plasma testosterone levels, and risk of hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst. 2000;92(24):2023-2028.
46. Yeh SH, et al. Somatic mutations at the trinucleotide repeats of androgen receptor gene in male hepatocellular carcinoma. Int J Cancer.2007;120(8):1610- 1617.
47. Jin F, Fondell JD. A novel androgen receptor-binding element modulates Cdc6 transcription in prostate cancer cells during cell-cycle progression. Nucleic Acids Res. 2009;37(14):4826-4838.
48. Wang Q, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138(2):245-256.
49. Liu Y, Wu C, Galaktionov K. p42, a novel cyclindependent kinase-activating kinase in mammalian cells. J Biol Chem. 2004;279(6):4507-4514. (Pubitemid 38199041)
50. Wohlbold L, et al. The cyclin-dependent kinase (CDK) family member PNQALRE/CCRK supports cell proliferation but has no intrinsic CDK-activating kinase (CAK) activity. Cell Cycle. 2006;5(5):546-554. (Pubitemid 43340534)
51. Wu GQ, et al. Cell cycle-related kinase supports ovarian carcinoma cell proliferation via regulation of cyclin D1 and is a predictor of outcome in patients with ovarian carcinoma. Int J Cancer. 2009;125(11):2631-2642.
52. An X, et al. Functional characterisation of cell cyclerelated kinase (CCRK) in colorectal cancer carcinogenesis. Eur J Cancer. 2010;46(9):1752-1761.
53. Satoh S, et al. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat Genet. 2000;24(3):245-250. (Pubitemid 30132191)
54. Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92(1):136-145. (Pubitemid 32623050)
55. Taniguchi K, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. 2002; 21(31):4863-4871. (Pubitemid 34879463)
56. Zucman-Rossi J, et al. Differential effects of inactivated Axin1 and activated beta-catenin mutations in human hepatocellular carcinomas. Oncogene. 2007;26(5):774-780. (Pubitemid 46204256)
57. Mulholland DJ, Dedhar S, Coetzee GA, Nelson CC. Interaction of nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to know? Endocr Rev. 2005;26(7):898-915. (Pubitemid 41770157)
58. McManus EJ, et al. Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis. Embo J. 2005;24(8):1571-1583. (Pubitemid 40646447)
59. Doble BW, Patel S, Wood GA, Kockeritz LK, Woodgett JR. Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell. 2007;12(6):957-971. (Pubitemid 46805920)
60. Buescher JL, Phiel CJ. A noncatalytic domain of glycogen synthase kinase-3 (GSK-3) is essential for activity. J Biol Chem. 2010;285(11):7957-7963.
61. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer. 2009;9(3):153-166.
62. Moon WS, et al. Expression of betacellulin and epidermal growth factor receptor in hepatocellular carcinoma: implications for angiogenesis. Hum Pathol. 2006;37(10):1324-1332. (Pubitemid 44380277)
63. Ueda S, et al. PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib. Cancer Res. 2006;66(10):5346-5353. (Pubitemid 43844960)
64. Lee TI, Johnstone SE, Young RA. Chromatin immunoprecipitation and microarray-based analysis of protein location. Nat Protoc. 2006;1(2):729-748.
65. Cougot D, et al. The hepatitis B virus X protein functionally interacts with CREB-binding protein/ p300 in the regulation of CREB-mediated transcription. J Biol Chem. 2007;282(7):4277-4287. (Pubitemid 47100918)
66. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995;378(6559):785-789. (Pubitemid 26004411)
67. Liver (including intrahepatic bile ducts). In: Greene FL, et al. eds. AJCC Cancer Staging Manual. 6th ed. Chicago, IL: Springer Press; 2002:131-138.